Simris Group (SIMRIS) investor relations material

Executive summary

• Net revenue for Q2 2026 fell 71% year-over-year to SEK 196k; interim period revenue down 27% to SEK 620k.

• EBITDA loss improved 35% in Q2 to SEK -1,927k and 39% for the interim period to SEK -4,110k.

• EBIT loss improved 19% in Q2 to SEK -5,437k and 21% for the interim period to SEK -11,063k.

• Significant management changes: new CEO for Simris Biologics and a new strategic advisor appointed.

• Divestment process for Hammenhög assets advanced with two prospective buyers.

Financial highlights

• Cash at period end increased to SEK 7,987k from SEK 1,026k year-over-year.

• Result before tax improved 17% in Q2 to SEK -6,751k and 8% for the interim period to SEK -13,724k.

• Cash flow from operating activities in Q2 was SEK -2,554k, down 34% year-over-year.

• Equity at period end was SEK 767k, up from SEK -7,745k a year earlier; solidity at 0.6%.

Outlook and guidance

• Ongoing warrant exercise expected to raise approximately EUR 1 million, extending financial runway.

• Board warns current cash reserves may not cover operations through year-end; active efforts underway to secure additional funding.